Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas

BACKGROUND: SEA-CD40 is an investigational, non-fucosylated, humanized monoclonal IgG(1) antibody that activates CD40, an immune-activating tumor necrosis factor receptor superfamily member. SEA-CD40 exhibits enhanced binding to activating FcγRIIIa, possibly enabling greater immune stimulation than...

Descripción completa

Detalles Bibliográficos
Autores principales: Coveler, Andrew L, Smith, David C, Phillips, Tycel, Curti, Brendan D, Goel, Sanjay, Mehta, Amitkumar N, Kuzel, Timothy M, Markovic, Svetomir N, Rixe, Olivier, Bajor, David L, Gajewski, Thomas F, Gutierrez, Martin, Lee, Hun Ju, Gopal, Ajay K, Caimi, Paolo, Heath, Elisabeth I, Thompson, John A, Ansari, Sahar, Jacquemont, Celine, Topletz-Erickson, Ariel, Zhou, Peigen, Schmitt, Michael W, Grilley-Olson, Juneko E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314623/
https://www.ncbi.nlm.nih.gov/pubmed/37385724
http://dx.doi.org/10.1136/jitc-2022-005584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314623/
https://www.ncbi.nlm.nih.gov/pubmed/37385724
http://dx.doi.org/10.1136/jitc-2022-005584

Ejemplares similares